- Sanofi's Q1 2025 sales surged to €9.9 billion, exceeding expectations by €120 million.
- Analysts forecast an 18.92% upside for Sanofi from its current stock price.
- The company maintains a positive outlook with anticipated double-digit earnings growth for 2025.
Sanofi (SNY, Financial) has made waves in the pharmaceutical industry with its recent financial performance. The company reported impressive first-quarter sales for 2025, totaling €9.9 billion, surpassing projections by €120 million. This robust growth, driven largely by the success of its asthma drug Dupixent, marks an 11% increase compared to the previous year. Sanofi is sticking to its forecast of mid-to-high single-digit sales growth and low double-digit earnings growth for the year, painting a promising picture for investors.
Wall Street Analysts Forecast
In the eyes of Wall Street, Sanofi SA (SNY, Financial) presents a compelling opportunity. Six analysts have provided one-year price targets, with an average target price set at $63.12. This target lies comfortably within a range from a high of $67.00 to a low of $56.00. The average target suggests a notable upside of 18.92% from Sanofi's current trading price of $53.08. For more price target details, explore our Sanofi SA (SNY) Forecast page.
Furthermore, the consensus from seven brokerage firms places Sanofi SA (SNY, Financial) with an average brokerage recommendation of 1.9, which translates to an "Outperform" rating. This recommendation is on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 suggests a Sell.
GuruFocus' GF Value for Sanofi SA (SNY, Financial) in the upcoming year is estimated to be $62.66. This figure indicates a potential upside of 18.05% from the current stock price of $53.08. The GF Value is a proprietary metric that considers the stock's historical trading multiples, past business growth, and future performance estimates. Investors looking to delve deeper into Sanofi's valuation can find extensive data on the Sanofi SA (SNY) Summary page.
